

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199943085 B2
(10) Patent No. 754469

(54) Title
A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer

(51)⁷ International Patent Classification(s)
A61K 031/445 A61K 047/18
A61K 009/00

(21) Application No: **199943085**

(22) Application Date: **1999.05.27**

(87) WIPO No: **WO99/62516**

(30) Priority Data

(31) Number	(32) Date	(33) Country
09/088128	1998.06.01	US

(43) Publication Date : **1999.12.20**

(43) Publication Journal Date : **2000.03.02**

(44) Accepted Journal Date : **2002.11.14**

(71) Applicant(s)
Schering Corporation

(72) Inventor(s)
Farah J. Munayyer; Frank Guazzo; Elliot I. Stupak; Imtiaz A. Chaudry; Joel A. Sequeira

(74) Agent/Attorney
GRIFFITH HACK,GPO Box 4164,SYDNEY NSW 2001

43085/99

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/445, 9/00, 47/18 // (A61K 31/445, 31:135)	A1	(11) International Publication Number: WO 99/62516 (43) International Publication Date: 9 December 1999 (09.12.99)
(21) International Application Number: PCT/US99/10469 (22) International Filing Date: 27 May 1999 (27.05.99) (30) Priority Data: 09/088,128 1 June 1998 (01.06.98) , US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: MUNAYYER, Farah, J.; 494 Passaic Avenue, West Caldwell, NJ 07006 (US). GUAZZO, Frank; 920 Ardsley Lane, Bridgewater, NJ 08807 (US). STUPAK, Elliot, I.; 11 Woodland Road, West Caldwell, NJ 07006 (US). CHAUDRY, Imtiaz, A.; 18 Rose Avenue, North Caldwell, NJ 07006 (US). SEQUEIRA, Joel, A.; 6 Mary Ellen Drive, Edison, NJ 08820 (US). (74) Agents: FRANKS, Robert, A. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A STABILIZED ANTIHISTAMINE SYRUP CONTAINING AMINOPOLYCARBOXYLIC ACID AS STABILIZER		
(57) Abstract An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.		

5

A STABILIZED ANTIHISTAMINE SYRUP CONTAINING AMINOPOLYCARBOXYLIC ACID AS STABILIZER

15

INTRODUCTION TO THE INVENTION

The present invention pertains to the field of liquid pharmaceutical formulations, and more particularly to syrup formulations containing antihistamines.

Syrup formulations are commonly used for delivery of pharmacological agents, particularly where the agents are to be delivered to pediatric patients. Traditional syrups are concentrated solutions of sugar (generally sucrose) in purified water, such as Syrup, NF prepared with 850 grams sucrose and sufficient water to make 1000 mL according to the procedure given in the official monograph at page 1990 of *NF XVII The National Formulary*, United States Pharmacopeial Convention, Inc., Rockville, Maryland U.S.A., 1990. However, for purposes of the present invention, the term "syrup" will also encompass those liquid formulations having a sweet taste provided wholly or partly by artificial sweeteners, such as saccharin, sorbitol, aspartame, sodium cyclamate and the like, for avoidance of dental and medical problems which may be aggravated by higher caloric sweeteners. As is well appreciated in the art, syrups frequently are flavored, such as with fruit or mint flavors, usually for purposes of masking an unpleasant taste caused by the presence of a dissolved or suspended pharmacologically active substance. A pleasant taste is particularly important when the formulation is intended for ingestion by children. Typical flavoring agents which are commonly used in

sweetened pharmaceuticals, foods, candies, beverages and the like are also useful in the present invention; these materials impart flavors such as grape, cherry, citrus, peach, strawberry, bubble gum, peppermint and many others.

Syrups frequently must contain antimicrobial components to ensure
5 safe storage without the proliferation of pathogenic molds, yeasts, bacteria and the like; a typical antimicrobial deemed suitable for use in foods and other ingestible substances is sodium benzoate. In addition, those syrups which do not contain sugar, or which contain a mixture of sugar and another sweetener, may contain thickening agents (such as a hydroxypropyl
10 methylcellulose, some forms of which are available from Dow Chemical, Midland, Michigan USA under the METHOCEL trademark) to provide a viscous mouth-feel similar to that of a traditional syrup.

An example of a currently marketed syrup contains 1 mg/mL of the antihistaminic drug loratadine, together with citric acid, artificial flavor,
15 glycerin, propylene glycol, sodium benzoate, sucrose and water; this formulation typically has a pH value between about 2 and 4. However, under certain storage conditions involving contact with the air, losses of loratadine content, and a concomitant generation of impurities, have occurred. Similar problems can occur with formulations containing other, chemically related,
20 drugs, such as descarboethoxyloratadine and azatadine.

J. S. Nairn, "Solutions, Emulsions, Suspensions and Extracts,"
Chapter 83 in A.R. Gennaro, Ed., *Remington's Pharmaceutical Sciences*, 18th
Ed., Mack Publishing Co., Easton Pennsylvania U.S.A., 1990 at pages 1519-
1520 discusses the problem of active agent stability in aqueous media. It is
25 stated that trace metal-initiated oxidation reactions can be minimized through the use of citric acid or EDTA sequestering agents.


It is desired to provide a storage-stable syrup formulation of loratadine or related antihistaminic components, which contains only components recognized as being safe for human ingestion.

SUMMARY OF THE INVENTION



In accordance with the invention, there is provided a syrup formulation containing an antihistamine selected from the group consisting of loratadine, descarboethoxyloratadine, azatadine and combinations of any two or more thereof, and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof. Suitable aminopolycarboxylic acids include ethylenediaminetetraacetic acid ("EDTA") and salts thereof, such as the disodium salt.

DETAILED DESCRIPTION OF THE INVENTION


Loratadine is the drug name given to the compound known as ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate and having the empirical formula $C_{22}H_{23}ClN_2O_2$. A structure for this compound is:



The compound descarboethoxyloratadine is an antihistaminic active metabolite of loratadine, having the following structure:



A closely related antihistamine is azatadine, having the following structural formula:



5

Degradation of syrup formulations containing loratadine or related antihistamines is observed during storage stability testing, as evidenced by declining concentrations of the active ingredient and a concomitant formation of impurities. Two of the impurities which form in loratadine syrups have been identified as 2-Hydroxymethyl loratadine ("2-HML") and 4-Hydroxymethyl loratadine ("4-HML"), while other unidentified impurities occur regularly and have been collectively denoted as "Group A"; these materials number about 5 to 7 and elute together in an HPLC analysis, at retention times which indicate a higher polarity than that of loratadine. The severity of the degradation may be at least approximately related to the volume in a product bottle which is not filled with syrup, i.e., the "headspace." As it is not practical to fill each bottle completely to the top, a test has been conducted where the headspace was filled with nitrogen gas; results were inconclusive, possibly due to the unavoidable oxygen permeability of the polymeric bottle closure.

Another test was conducted, wherein common antioxidant additives were incorporated into the syrup. Ideally, the antioxidant will be soluble in the syrup and is safe for use in foods and pharmaceutical preparations. Among the water-soluble materials, ascorbic acid at 0.1 and 1 mg/mL was found to somewhat reduce degradation, but also caused an unacceptable strong color change in the product, while sodium bisulfite imparted a pungent, disagreeable odor to the syrup. The oil-soluble antioxidants butylated hydroxytoluene and tocopherol were not soluble in the syrup, so also were not found acceptable.

It has been found that the addition of small amounts of an aminopolycarboxylic acid, the term specifically including salts of the acids, can stabilize the syrups against degradation. Useful aminopolycarboxylic acids and salts thereof are those which are safe for ingestion and have
5 sufficient solubility in the syrup formulations to make a stable single phase composition. Commercially available compounds which could be used include iminodiacetic acid, methyliminodiacetic acid, nitrilotriacetic acid, ethylenediaminetetraacetic acid ("EDTA"), diethylenetriaminepentaacetic acid, 1,2-diaminocyclohexane-tetraacetic acid, N-hydroxyethylenediaminetriacetic
10 acid and related compounds. Mixtures of two or more of the foregoing are suitable for use. From the aspects of ready availability, safety, efficacy and cost, the alkali metal salts of EDTA are presently preferred, and the remainder of this description will focus on those materials.

An aminopolycarboxylic acid or salt will typically be present in a syrup
15 at about 0.05 mg/mL to about 5 mg/mL. More preferably, the level of aminopolycarboxylic acid will be about 0.1 mg/mL to about 1 mg/mL. As with any additive component in a formulation intended for ingestion, it is desirable to incorporate the minimum level which will yield the desired result. This level can be readily determined by means of an accelerated storage stability
20 test, in which packages of the final product are stored at elevated temperatures above the usual storage temperatures to which the product is expected to be exposed; the present inventors have used temperatures up to 55°C for this purpose, although such temperatures tend to cause a minor discoloration (darkening) of the syrups, probably due to some caramelization
25 of the contained sucrose. It is expected that most drug degradation reactions will be accelerated by the elevated temperature. At predetermined intervals, some of the packages are opened and analyzed to determine the amount of active ingredients and impurities present in the formulation.

Antihistaminic syrup formulations frequently also contain other drugs,
30 for obtaining more than one therapeutic result from a single dose. Typical drug substances included with the antihistamine are sympathomimetic amine decongestants, such as pseudoephedrine or phenylpropanolamine

(for relief of the upper airway congestion often accompanying disorders such as rhinitis and upper respiratory infections), and analgesics, such as aspirin, acetaminophen, ibuprofen, naproxen or ketoprofen (for relief of pain and, except in the case of acetaminophen, for reducing inflammation).

- 5 Antitussives, such as codeine, hydrocodone or dextromethorphan, for relief from coughing, and expectorants such as guaifenesin, for increasing cough productivity, also are included in combination products. Any of these additional ingredients, including salts thereof and other drugs from the same therapeutic classes, are suitable for inclusion in the syrups of the present
10 invention.

The invention will be further described by means of the following examples, which are not intended to limit the scope of the invention as defined by the appended claims. Where the term "percent" is used herein, it is intended to represent percent by weight, unless the context clearly
15 evidences otherwise.

EXAMPLE 1

A syrup was formulated to contain the following ingredients, wherein
20 amounts of all except water are expressed in milligrams.

	<u>Ingredient</u>	<u>Amount</u>
	Loratadine, micronized	1
25	Citric acid	8.78
	Flavoring agent	2.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
30	Disodium EDTA	0.25
	Sucrose	600
	Water	to make 1.0 mL

This syrup is prepared using the following procedure: (a) about 80 percent of the water is placed in a vessel, heated to 75-85°C, charged with the sugar and stirred to form a solution; (b) the citric acid is charged to the solution and stirring is continued to form a solution, then the sodium benzoate is added and dissolved; (c) the solution is cooled to 30-35°C, with continued stirring, and the disodium EDTA is added and dissolved; (d) the glycerin is added and stirring continued while the solution cools to 25-30°C; (e) in a separate vessel, the propylene glycol and loratadine are combined and stirred to form a solution (note that the use of micronized loratadine particles decreases the time required to accomplish dissolution), then the flavoring agent is added and stirred to achieve homogeneity; (f) the product of step e is combined with the product of step d, with stirring to ensure homogeneity, and sufficient water is added to provide the proper formulation weight; and (g) the resulting syrup is passed through clarifying filters. The syrup is a clear, colorless liquid (which could readily be colored as desired, such as by adding a suitable pharmaceutically acceptable water-soluble dye to the sugar solution of step a) and is denoted Sample A.

Another syrup is similarly formulated, except that it further contains 1 mg/mL of the disodium salt of EDTA. This is denoted Sample B.

Twenty five mL portions of the two syrups are placed into 50 mL flint glass vials, then sealed with rubber stoppers and aluminum caps. The sealed vials are stored at 55°C until their removal and analysis by high performance liquid chromatography. Results of the analyses are as follows, where "NQ" indicates a result below the limit of quantification (0.1%) but above the limit of detection (0.02%):

	<u>Sample</u>	<u>Storage (weeks)</u>	<u>Percent Degradation Products</u>		
			<u>2-HML</u>	<u>4-HML</u>	<u>Total</u>
5	A	3	0.23	0.19	0.42
		6	0.33	0.32	0.81 ^a
10	B	3	0.11	NQ	0.11
		6	0.10	NQ	0.10
		12	0.15	0.14	0.62 ^b

^a Sample contained 0.16% of an unidentified degradation product

^b Sample contained two unidentified degradation products at levels of 0.21% and 0.12%

15 These results indicate a significant inhibition by EDTA of the degradation of loratadine during the severe storage conditions of the test.

EXAMPLE 2

20 Sample A from the preceding example and similarly prepared syrups which also contain 0.1, 0.25, 0.5 or 0.75 mg/mL of disodium EDTA are packaged as in the prior example, and stored and tested similarly. The following results are obtained, where "ND" indicates a concentration below the limit of detection previously stated.

	<u>EDTA (mg/mL)</u>	<u>Storage (weeks)</u>	<u>Percent Degradation Products</u>		
			<u>2-HML</u>	<u>4-HML</u>	<u>Total</u>
30	0	3	0.25	0.21	0.69 ^a
		6	0.29	0.24	0.67 ^b
		9	0.49	0.53	1.54 ^c

-9-

	0.1	3	NQ	NQ	NQ
		6	0.10	NQ	0.10
		9	0.12	0.11	0.33 ^d
5	0.25	3	NQ	NQ	NQ
		6	NQ	NQ	NQ
		9	0.10	NQ	0.10
10	0.5	3	NQ	ND	NQ
		6	0.10	ND	0.10
		9	0.11	0.10	0.21
15	0.75	3	NQ	NQ	NQ
		6	0.10	ND	0.10
		9	0.10	0.10	0.20

^a Sample contained 0.11% of Group A degradation products and 0.12% of an unidentified degradation product

^b Sample contained 0.14% of an unidentified degradation product

20 ^c Sample contained three unidentified degradation products at levels of 0.17%, 0.13% and 0.22%

^d Sample contained 0.10% of an unidentified degradation product

25 These results suggest that 0.25 percent disodium EDTA would be a reasonable level for storage protection of the tested syrup.

EXAMPLE 3

30 A stabilized syrup is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

-10-

	<u>Ingredient</u>	<u>Amount</u>
	Loratadine, Micronized	1
	Citric acid	8.78
5	Flavoring agent	1.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
	Disodium EDTA	0.25
10	Coloring agent	1
	Sucrose	400
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

15

EXAMPLE 4

A stabilized syrup is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

20

	<u>Ingredient</u>	<u>Amount</u>
	Loratadine, micronized	1
25	Citric acid	0.48
	Sodium citrate	0.6
	Flavoring agent	1.5
	Glycerin	350
	Propylene glycol	100
30	Sorbitol	150
	Sodium benzoate	1
	Disodium EDTA	0.25

-11-

Sodium cyclamate	0.75
Hydroxypropyl methylcellulose	0.5
Coloring agent	1
Water	to make 1.0 mL

5

This syrup is found to exhibit acceptable storage stability. METHOCEL™ K100M, K4M and A4M from Dow Chemical are among the hydroxypropyl methylcellulose products which are suitable for use in the invention; substituting the various available products can cause syrup viscosity changes, so experiments should be conducted to determine the appropriate grade and amount needed to prepare a given syrup with desired properties.

10

EXAMPLE 5

15

A stabilized syrup is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

20	<u>Ingredient</u>	<u>Amount</u>
	Loratadine, micronized	1
	Citric acid	0.48
	Sodium citrate	0.6
25	Flavoring agent	1
	Glycerin	350
	Propylene glycol	100
	Sorbitol	150
	Sodium benzoate	1
30	Disodium EDTA	0.25
	Saccharin	0.75
	Hydroxypropyl methylcellulose	0.5

Water to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

5

EXAMPLE 6

A stabilized syrup is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

10

	<u>Ingredient</u>	<u>Amount</u>
	Loratadine	1
	Citric acid	0.48
15	Sodium citrate	0.6
	Flavoring agent	2.5
	Glycerin	450
	Sorbitol	250
	Propylene glycol	100
20	Sodium benzoate	1
	Disodium EDTA	0.25
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

25

EXAMPLE 7

A stabilized syrup is formulated according to the previously described general procedure, but substituting descarboethoxyloratadine for loratadine, to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

30

	<u>Ingredient</u>	<u>Amount</u>
	Descarboethoxyloratadine	1
	Citric acid	8.78
5	Flavoring agent	2.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
	Disodium EDTA	0.25
10	Sucrose	400
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

15

EXAMPLE 8

A stabilized syrup is formulated according to the previously described general procedure, but substituting azatadine for loratadine, to contain the following ingredients, wherein amounts of all except water are expressed in

20 milligrams.

	<u>Ingredient</u>	<u>Amount</u>
	Azatadine	1
25	Citric acid	8.78
	Flavoring agent	2.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
30	Sucrose	600
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

EXAMPLE 9

- 5 A stabilized syrup for pediatric use is formulated according to the previously described general procedure to contain the following ingredients, wherein amounts of all except water are expressed in milligrams.

	<u>Ingredient</u>	<u>Amount</u>
10	Loratadine	0.5
	Pseudoephedrine sulfate	3
	Acetaminophen	32
	Dextromethorphan hydrobromide	1.5
	Citric acid	8.78
15	Flavoring agent	1.5
	Glycerin	100
	Propylene glycol	100
	Sodium benzoate	1
	Disodium EDTA	0.25
20	Coloring agent	1
	Sucrose	400
	Water	to make 1.0 mL

This syrup is found to exhibit acceptable storage stability.

25

It is to be understood that a reference herein to a prior art document does not constitute an admission that the document forms part of the common general knowledge in the art in Australia or in any other country.



WHAT IS CLAIMED IS:

1. A syrup formulation containing an antihistamine selected from the group consisting of loratadine, descarboethoxyloratadine, azatadine and combinations of
5 any two or more thereof, and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

2. The syrup formulation of claim 1, wherein an aminopolycarboxylic acid comprises about 0.1 to about 1 mg/mL.
10

3. The syrup formulation of claim 1, wherein an aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.

4. The syrup formulation of any of claims 1-3, wherein an
15 aminopolycarboxylic acid is selected from the group consisting of iminodiacetic acid, methyliminodiacetic acid, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, 1,2 diaminocyclohexanetetraacetic acid, N-hydroxyethylenediaminetetraacetic acid, salts of any of the acids and any combination of two or more of the acids or salts.

5. The syrup formulation of any of claims 1-4, further containing a
20 decongestant, analgesic, antitussive, expectorant or any combination of two or more thereof.

6. The syrup formulation of any of claims 1-4, further containing a
25 decongestant selected from the group consisting of pseudoephedrine, phenylpropanolamine and their salts.

7. The syrup formulation of either of claims 5 or 6, wherein a decongestant
30 is pseudoephedrine or a salt thereof.

8. The syrup formulation of any of claims 1-7, wherein an antihistamine is loratadine.



9. The syrup formulation of any of claims 1-7, wherein an antihistamine is descarboethoxyloratadine.

5 10. The syrup formulation of any of claims 1-9, wherein an aminopolycarboxylic acid is ethylenediaminetetraacetic acid or a salt thereof.

11. The syrup formulation of any of claims 1-10, wherein an aminopolycarboxylic acid is present in an amount sufficient to inhibit degradation of the
10 antihistamine.

12. An antihistamine syrup formulation substantially as herein described with reference to any of Examples 1 to 9.

15 Dated this 2nd day of July 2001

SCHERING CORPORATION

By their Patent Attorneys

GRIFFITH HACK

